90 results about "Igm antibody" patented technology

The invention relates to the field of in-vitro immunodiagnosis detection, in particular to an IgG antibody, an IgM antibody and a method. The invention provides an IgG (immunoglobulin G) antibody specifically bound with coxsackie virus, which is characterized in that amino acid sequences of complementary determining regions CDRH1-CDRH3 of a heavy chain variable region of the IgG antibody are respectively shown as SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3; the amino acid sequences of the complementary determining regions CDRL1-CDRL3 of the light chain variable region are respectively as shown in SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6. The IgG antibody provided by the invention not only has good specificity and can specifically recognize the coxsackie virus, but also has high sensitivity and stability.

The present disclosure relates to proteases that exhibit activity against immunoglobulins, particularly IgM antibodies, and uses of the proteases for analysis of IgM, for generation of IgM antibody fragments, diagnostics related to IgM antibodies, and for treating and / or preventing diseases mediated by IgM antibodies.

The invention relates to the technical fields of gene engineering, antibody engineering and immunodiagnosis. The invention provides a recombinant humanized anti-Cpn IgM monoclonal antibody. The monoclonal antibody comprises a light chain variable region and a heavy chain variable region, the light chain variable region comprises three complementary determining regions CDR1, CDR2 and CDR3, and the amino acid sequences of the three complementary determining regions are respectively shown as SEQ ID NO.3, SEQ ID NO.4 and SEQ ID NO.5; the heavy chain variable region comprises three complementary determining regions CDR1, CDR2 and CDR3, and the amino acid sequences of the three complementary determining regions are shown as SEQ ID NO.6, SEQ ID NO.7 and SEQ ID NO.8 respectively. The invention also provides a method for preparing the monoclonal antibody. The recombinant humanized anti-Cpn IgM monoclonal antibody provided by the invention is expressed in mammalian cells by utilizing a gene recombination technology, has the characteristics of high purity, small batch difference and the like, and can be applied to a Cpn IgM antibody detection kit as a quality control product; as a quality control product, the recombinant humanized anti-Cpn IgM monoclonal antibody has the advantages of high sensitivity, high safety, inter-batch stability and the like.

The invention discloses a recombinant protein for detecting an anti-myelin sheath related glycoprotein MAG antibody and a detection reagent of the recombinant protein, and belongs to the technical field of neural immunodiagnostics, five amino acid sites in MAG protein are subjected to specific amino acid point mutation replacement to obtain an MAG protein mutation sequence, the MAG protein mutation sequence is fused with GlcATP enzyme and HNK-1ST enzyme full-length sequences to construct a lentiviral expression vector, and the recombinant protein and the detection reagent are used for detecting the anti-myelin sheath related glycoprotein MAG antibody. According to the present invention, three genes are constructed, and are stably transfected in a host cell so as to stably express the three genes in one cell at the same time, such that the constructed recombinant protein and the wild type MAG protein have similar anti-MAG IgM antibody binding domain, and on the premise of not using GlcATP enzyme and HNK-1ST enzyme small molecule agonists, the sensitivity and the specificity of the detection of the MAG autoimmune antibody by using the CBA method are improved; the method is suitable for preparing related detection reagents for in-vitro detection of the IgM type anti-MAG antibody.

The invention relates to an antibody detection kit for detecting chronic inflammatory demyelinating multiple nerve root neuropathy and a preparation method of the antibody detection kit. The antibody detection kit for detecting the chronic inflammatory demyelinating multiple nerve root neuropathy comprises an IgG antibody detection strip, an IgM antibody detection strip, a working solution and an auxiliary agent. The antibody detection kit disclosed by the invention can be used for simultaneously detecting nine autoantibodies related to the chronic inflammatory demyelinating multiple nerve root neuropathy, wherein the nine autoantibodies comprise NF155, NF186, CNTN1, CNTN2, CASPR1, CASPR2, GLIOMEDIN, NRCAM and MAG. The design of simultaneous detection of multiple antigens greatly improves the comprehensiveness of detection, so that multiple possible pathogenic factors can be covered in single detection, and the problem of missed diagnosis caused by single antibody detection is avoided.

The invention provides detection test paper and a detection kit for detecting an IgG / IgM antibody. The detection test paper comprises a marking pad, a sample pad, a detection pad and a water absorption pad which are adhered to a bottom card and are sequentially overlapped from upstream to downstream, the detection pad is coated with an IgG detection line and an IgM detection line, and the IgG detection line is located at the upstream of the IgM detection line; during detection, the sample reaches the detection line of the detection pad before the marker. The detection test paper is simple in structure, convenient to use, high in anti-interference capacity and high in detection sensitivity, and the detection kit can improve the accuracy, early diagnosis and early treatment of early diagnosis of diseases such as infectious diseases, so that transmission of the infectious diseases is reduced.

The invention discloses an anti-IgM antibody and application thereof, and relates to the field of antibodies. The anti-human IgM antibody disclosed by the invention comprises a heavy chain complementarity determining region and a light chain complementarity determining region, has good effects of blocking and eliminating immune interference, and provides an important blocking agent raw material.

The invention discloses mannheimia haemolytica outer membrane vesicles as well as a preparation method and application thereof, and belongs to the technical field of bioengineering. The OMV is separated from Mh-5 strain culture supernatant through tangential flow ultrafiltration combined with an ultracentrifugation technology, and animal experiments prove that a high-level IgG / IgM antibody can be induced by intramuscular injection of 50 micrograms per mouse, expression of inflammatory factors such as IL-6 and TNF-alpha of the spleen is remarkably improved, the protection rate after challenge reaches 85.7%, and pathological damage is remarkably lighter than that of an inactivated vaccine group. According to the scheme provided by the invention, the problems of insufficient serotype coverage and antibiotic resistance in the prior art are solved, and a new strategy is provided for prevention and control of mannheimia haemolytica.

The invention provides a joint detection test strip for dengue virus and Zika virus antigens and antibodies and a preparation method of the joint detection test strip. According to the combined detection test strip, the combined detection test strip with the dengue virus NS1 antigen and the dengue virus IgG / IgM antibody adopts a multi-site recombinant antigen labeling or multi-site recombinant antibody coating form, so that the sensitivity of a reagent is improved; the problems of poor specificity and release residue of latex microspheres are solved by optimizing the confining liquid; colored latex microspheres are used as a marker, a detection target is more intuitively distinguished according to line colors, clinical result interpretation is facilitated, the accuracy of dengue virus infection and Zika virus infection is more quickly improved, and the dengue virus NS1, the Zika virus NS1 antigen, the dengue virus IgG / IgM antibody and the Zika virus IgG / IgM antibody can be detected at the same time; and the kit is convenient to carry, simple to operate, convenient for on-site instant detection and capable of performing large-scale preliminary screening.

A composition and method for therapeutic or prophylactic treatment of mammals includes a mixture of IgY antibodies derived from one or more eggs laid by one or more avian species, wherein each of the one or more avian species have been vaccinated with one or more of the plurality of antigens. The mixture of IgY antibodies can be combined with a protective material that includes colostrum. In some embodiments the composition can also include IgA and IgM antibodies.

The present invention belongs to the field of biomedicine technology, and discloses a specific epitope polypeptide, a kit and an application thereof. The present invention provides a SARS-CoV-2 specific epitope polypeptide associated with neutralizing activity, and its amino acid sequence is shown in SEQ ID No.2. The present invention designs and constructs a SARS-CoV-2 polypeptide microarray, analyzes the IgG and IgM antibody responses induced by the SARS-CoV-2 inactivated vaccine, screens out a series of immune epitope polypeptides associated with the neutralizing activity of antibodies, and establishes a polypeptide indirect ELISA detection kit on this basis. The method has high sensitivity, good specificity, good repeatability and stability, and does not require a high-level biosafety laboratory. It is easy to operate, objective in judging the results, and can achieve the purpose of quickly evaluating the level of new crown vaccine antibodies, providing new means and directions for new crown antibody detection methods.

The invention discloses an early and late latent syphilis prediction model based on a treponema pallidum nonspecific IgM antibody, and relates to the technical field of biology. The objective of the invention is to solve the problem of inaccurate latent syphilis staging caused by dependence on subjective recall and single index in the prior art. The prediction model is a hume diagram model and comprises three indexes, namely a treponema pallidum non-specific IgM antibody, a treponema pallidum specific antibody and a treponema pallidum non-specific antibody. The method provides a basis for timely and accurately performing medical intervention on early and late latent syphilis patients, and has an important clinical application value.

The present invention relates to the technical field of antibody storage, and specifically to an anti-contamination test kit for detecting IgM antibodies and a sealing method thereof, comprising: a test kit body, on which a cover plate is rotatably mounted; a loading assembly, which comprises a No. 1 support plate and a No. 2 support plate; a lifting assembly, which can drive the No. 1 support plate and the No. 2 support plate to move toward the upper part of the test kit body when the cover plate is opened; a pulling assembly, which is arranged between the No. 1 support plate and the No. 2 support plate, and can move the No. 2 support plate toward the No. 1 support plate when the No. 1 support plate rises to a high point of its travel; a clamping assembly, which is arranged between the No. 1 support plate and the test kit body, and is connected to an arc-shaped rubber piece, and can drive the arc-shaped rubber piece to abut against a test tube inserted between the No. 1 support plate and the No. 2 support plate when the No. 1 support plate descends to a low point of its travel, so as to prevent the test tube from shaking in the test kit and breaking.

The present invention discloses a recombinant protein for detecting anti-myelin associated glycoprotein (MAG) antibody and a detection reagent thereof, belonging to the technical field of neuro-immunodiagnosis. By performing specific amino acid point mutation substitutions at five amino acid positions in the MAG protein, a MAG protein mutant sequence is obtained, and then it is fused with the full-length sequences of GlcATPase and HNK-1ST enzyme to construct a lentiviral expression vector, which is stably transfected into host cells, enabling the simultaneous stable expression of the three genes in one cell. The constructed recombinant protein has a similar anti-MAG IgM antibody binding domain to the wild-type MAG protein, and without using small molecule agonists of GlcATPase and HNK-1ST enzyme, it improves the sensitivity and specificity of detecting MAG autoantibodies by the CBA method, and is suitable for preparing related detection reagents for in vitro detection of IgM-type anti-MAG antibodies.

The application provides a combined detection test strip for dengue virus, Zika virus antigen and antibody and a preparation method thereof; the combined detection test strip of the application adopts a multi-site recombinant antigen marking or multi-site recombinant antibody coating form for the combined detection test strip for dengue virus NS1 antigen and dengue virus IgG / IgM antibody, thereby improving the sensitivity of the reagent; the application also overcomes the problems of poor specificity and release residue of the latex microspheres by optimizing a blocking solution; color latex microspheres are used as the markers, the target is more intuitively detected according to the color of the lines, clinical result interpretation is facilitated, the accuracy of dengue virus infection and Zika virus infection is improved, dengue virus NS1, Zika virus NS1 antigen, dengue virus IgG / IgM antibody detection and Zika virus IgG / IgM antibody can be simultaneously detected; moreover, the application is convenient to carry and easy to operate, is convenient for on-site instant detection and can be used for large-scale preliminary screening.

The present application relates to the field of biotechnology, and more particularly to a SNP marker related to the level of anti-streptococcus agalactiae IgM antibody of tilapia and application thereof. The present application screens out QTLs, functional genes and key signal pathways significantly related to the level of anti-streptococcus agalactiae IgM antibody of tilapia by RNA-Seq and BSA-Seq technologies, and further identifies two SNP markers closely related to the level of anti-streptococcus agalactiae IgM antibody of tilapia, thereby providing important genetic targets and tools for molecular marker-assisted breeding of anti-streptococcus agalactiae of tilapia.

The present invention relates to an IgM antibody formulation and uses thereof. In particular, the IgM antibody formulation comprises an IgM antibody, which is an IgM antibody formed by a nanobody fusion protein and a J chain, the nanobody fusion protein is a fusion protein comprising a nanobody and an Fc fragment, which are optionally linked by a linker, wherein the formulation further comprises a buffer selected from a citrate buffer system, optionally the formulation further comprises one or more of a stabilizer, an osmotic pressure regulator and a surfactant.

An immunological analysis mode of a novel total antibody assay and a kit for detecting antibodies of infectious diseases in human blood samples according to the mode, the kit comprising: a first reagent containing at least one antigen coated on a solid support and an anti-human IgM antibody coated on a solid support; and a second reagent containing at least one labeled antigen and a labeled anti-human IgG antibody; wherein at least one antigen of the at least one antigen coated on the solid support and at least one antigen of the at least one labeled antigen can bind to the same IgG antibody or the same IgM antibody in the sample. The kit can overcome the disadvantages caused by the detection principle while retaining the advantages of each detection principle. In addition, a method for detecting antibodies produced after pathogen infection in a sample is provided.

The present invention relates to a glycosylated IgM antibody that cross-specifically binds to an IgG antibody and a complexing molecule, such as DNA, wherein binding to the IgG antibody and the complexing molecule induces degradation of the IgG antibody. The Kd of the binding affinity of the IgM antibody to the IgG antibody is preferably in the range of 10 <-5 > to 10 <-8 >. The invention also relates to medical uses of the glycosylated IgM antibody, such as in the treatment of autoimmune diseases, such as systemic lupus erythematosus, rheumatoid arthritis and multiple sclerosis.

The present invention relates to an immunoassay for the detection of Borrelia specific IgG, IgM and IgG / IgM antibodies in biological samples suspected of Lyme infection. The immunoassay can be performed via a standard immunoassay format or on an automated platform. In various embodiments, the immunoassay uses one or more Borrelia specific chimeric peptides VlsE-FlaB (designated pFlaB-mV), VlsE-ErpP (designated pErp59-mV), VlsE-P35 (designated pP35-mV) alone or in combination with one or more outer surface protein C (Osp C) types B or I, p58 and DbpA. Other aspects of the invention provide antigen / substrate combinations and compositions comprising combinations of the disclosed peptides and / or proteins for use in the immunoassays described herein.

The invention relates to the field of in-vitro immunodiagnosis detection, in particular to an IgG antibody of mumps virus, a recombinant IgM antibody and application. Wherein the IgG antibody comprises a heavy chain constant region, a light chain constant region, and a heavy chain variable region and a light chain variable region of the IgG monoclonal antibody which is specifically combined with the mumps virus, and the IgG monoclonal antibody is of a mouse source or a rabbit source. According to the present invention, the IgG antibody is modified to obtain the recombinant IgM antibody, and the IgG antibody and the recombinant IgM antibody are not only suitable for the chemiluminescence method, but also show the expected sensitivity amplification factor in other immunological detection methods, such that the low-abundance detection of the specifically bound mumps virus can be easily achieved.

The invention discloses a non-human animal integrated with a double-derived VH subclass fusion gene as well as a construction method and application of the non-human animal. The method comprises the following steps: firstly, constructing a gene construct containing human IGHV1-69 and IGHV3-23 fragments, a specific spacer region, a functional element and a rat heavy chain 3'enhancer, and microinjecting the gene construct into a C57BL / 6J fertilized egg with an endogenous heavy chain and a kappa light chain knocked out to obtain a transgenic mouse; through identification, after a mouse endogenous antibody is inactivated, a human gene is stably integrated, a human IgM antibody is expressed and H5N1 HA immunization is carried out, the use frequency of IGHV1-69 is remarkably increased, the mouse produces a high-titer specific antibody, and serum has neutralizing activity. The mouse can generate a target bnAbs aiming at the HA stem and the RBS in parallel, so that the antibody screening efficiency is improved, and an in-vivo screening and evaluation platform for simulating human body fluid response is provided for research and development of influenza antibodies and vaccines.

Provided herein are antibodies, such as IgM antibodies, that bind to human PSGL-1. These antibodies can be used in a variety of diagnostic and therapeutic methods, including, without limitation, treating T-cell mediated inflammatory diseases, cancers, transplantations, and transfusions.

The present invention provides an anti-mutant citrullinated vimentin antibody detection kit and its application, which relates to the field of biotechnology. The kit includes a mutant citrullinated vimentin-coupled magnetic particle working solution, which is mixed with a final feed ratio of 0.6 ng / (unit × mL) mutant citrullinated vimentin polypeptide E1-coupled magnetic particles, 0.3 ng / (unit × mL) mutant citrullinated vimentin polypeptide H1-coupled magnetic particles, 0.3 ng / (unit × mL) mutant citrullinated vimentin polypeptide G5-coupled magnetic particles and a buffer; a tracer-labeled antibody working solution, which is composed of a tracer-labeled anti-human IgM antibody and a diluent. The kit of the present invention uses a mixture of mutant citrullinated vimentin polypeptide E1-coupled magnetic particles, mutant citrullinated vimentin polypeptide H1-coupled magnetic particles, and mutant citrullinated vimentin polypeptide G5-coupled magnetic particles to greatly improve sensitivity and specificity.

The invention relates to the technical field of recombinant antibody expression, in particular to a molecular chaperone PDI for improving IgM recombinant expression efficiency and application of the molecular chaperone PDI, and the molecular chaperone PDI comprises an amino acid sequence as shown in SEQ ID NO: 3. By means of molecular chaperone co-expression, the expression stability of IgM can be remarkably improved, meanwhile, the flow detection signal intensity of the recombinant expression IgM antibody is equivalent to that of a commercial IgM antibody from hybridoma, the expression condition of the recombinant antibody is stable, the batch-to-batch difference in the batch production process is small, and the production cost is low. The recombinant expression can better avoid the risk of antibody gene sequence loss (such as non-expression) generated in the continuous production process of the hybridoma, and also can avoid possible variation (such as glycosylation difference) of antibodies secreted in different batches, so that an optimization strategy is provided for recombinant expression of IgM.

The invention relates to the technical field of blood routine examination, and discloses a condensation element removing device and method, and the condensation element removing device comprises a first container, a second container, a filter screen and a carrier. The blood collection tube, the first container and the second container are assembled and uniformly mixed up and down, a detection sample moves back and forth in the blood collection tube and the second container, and when the detection sample flows to the second container from the blood collection tube and the first container, blood cells are intercepted by the filter screen, and blood plasma without the blood cells enters the second container, so that the blood collection tube and the second container are separated from each other. And combining condensed elements in the filtered plasma with an anti-human IgM antibody on the surface of the carrier, fixing the condensed elements on the surface of the carrier, pouring the reacted plasma into a first container and a blood collection tube, fully and uniformly mixing the reacted plasma with blood cells, and carrying out clinical blood routine examination. Theoretically, the process does not cause cell loss, red blood cells do not agglutinate again due to temperature change, and the method is more favorable for helping clinical laboratories to solve the problems of tedious treatment, long time consumption and the like of condensation set samples.

Disclosed herein is use of a Rickettsia OmpB β-peptide epitope that binds host immune IgM as a specific diagnostic substrate for detecting patient immune IgM antibody to both spotted fever group and typhus group Rickettsia.

This invention relates to the field of biological detection, and in particular to an IgM antibody for preventing erythrocyte agglutination, its preparation method, and its uses. The IgM antibody for preventing erythrocyte agglutination is obtained by mixing and incubating a natural IgM antibody with DTT. The IgM antibody can be used to prepare products for detecting ABO blood types and products for detecting the expression levels of type A antigen and / or type B antigen. The prepared products can be used for quantitative detection of ABO antigen expression, studying changes in ABO antigen expression levels among different genotypes, and studying diseases related to ABO antigen expression levels.

The invention relates to the technical field of biology, in particular to an anti-human IgM antibody or a functional fragment thereof and application of the anti-human IgM antibody or the functional fragment thereof, and discloses an anti-human IgM antibody or an antigen binding part antibody thereof, which has high affinity and stable performance on IgM, can block endogenous interferent rheumatoid factors, and has great significance on obtaining correct diagnosis results.

The invention provides a buffer solution for reducing interference of rheumatoid factors in IgM antibody capture method detection, the buffer solution contains 0.05-5% by mass of poly-human IgG, and the polymerization degree of the poly-human IgG is 8-14. The buffer solution has the best binding capacity with RF, and when the buffer solution is used as a buffer diluent for IgM antibody detection, the accuracy of IgM antibody detection can be ensured.